Common use of Nasdaq Stock Market Clause in Contracts

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Market under the symbol [“RSLS”] (it being understood that the trading symbol will be changed in connection with the Merger). There is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 2 contracts

Samples: Subscription Agreement (ReShape Lifesciences Inc.), Subscription Agreement (ReShape Lifesciences Inc.)

AutoNDA by SimpleDocs

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Global Market under the symbol [RSLS”] RPHM” (it being understood that the trading symbol will be changed in connection with the MergerMergers). There is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Global Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 2 contracts

Samples: Subscription Agreement (Reneo Pharmaceuticals, Inc.), Merger Agreement (Reneo Pharmaceuticals, Inc.)

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Global Market under the symbol [RSLSNGNE] (it being understood that . The Company is in compliance with all listing requirements of Nasdaq applicable to the trading symbol will be changed in connection with Company. As of the Merger). There date hereof, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Global Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Securities Purchase Agreement (Neurogene Inc.)

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Market under the symbol [RSLSSNTI] (it being understood that . The Company is in compliance with all listing requirements of Nasdaq applicable to the trading symbol will be changed in connection with the Merger)Company. There is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof of this Agreement that is designed to to, or could reasonably be expected to, terminate the listing of the Common Stock on the Nasdaq Capital Market or the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Securities Purchase Agreement (Senti Biosciences, Inc.)

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Global Select Market under the symbol [RSLS”] (it being understood that XXXX.” As of the trading symbol will be changed in connection with the Merger). There date hereof, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Global Select Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Stock Purchase Agreement (LENZ Therapeutics, Inc.)

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Market under the symbol [RSLSTENX] (it being understood that . The Company is in compliance with all listing requirements of Nasdaq applicable to the trading symbol will be changed in connection with the Merger)Company. There is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Securities Purchase Agreement (Tenax Therapeutics, Inc.)

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Market under the symbol [RSLSAADI] (it being understood that . As of the trading symbol will be changed in connection with the Merger). There date hereof, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Securities Purchase Agreement (Aadi Bioscience, Inc.)

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Global Market under the symbol [RSLS”] GRPH” (it being understood that the trading symbol will be changed in connection with the Merger). There As of the date hereof, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Global Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Subscription Agreement (Graphite Bio, Inc.)

AutoNDA by SimpleDocs

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Global Market under the symbol [RSLSACRV] (it being understood that . The Company is in compliance with all applicable listing requirements of Nasdaq applicable to the trading symbol will be changed in connection with Company. As of the Merger). There date hereof, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Global Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Securities Purchase Agreement (Acrivon Therapeutics, Inc.)

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Global Market under the symbol [RSLSKALV] (it being understood that . The Company is in compliance with all listing requirements of Nasdaq applicable to the trading symbol will be changed in connection with Company. As of the Merger). There date of this Agreement, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Global Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof of this Agreement that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Securities Purchase Agreement (KalVista Pharmaceuticals, Inc.)

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Global Select Market under the symbol [RSLSXXXX] (it being understood that . The Company is in compliance with all listing requirements of Nasdaq applicable to the trading symbol will be changed in connection with the Merger)Company. There is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Global Select Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof of this Agreement that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Securities Purchase Agreement (Day One Biopharmaceuticals, Inc.)

Nasdaq Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Global Market under the symbol [RSLS”] (it being understood that REPL.” The Company is in compliance with all applicable listing requirements of Nasdaq applicable to the trading symbol will be changed in connection with Company. As of the Merger). There date hereof, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by the Nasdaq Stock Market or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Capital Global Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date hereof that is designed to terminate the registration of the Common Stock under the Exchange Act.

Appears in 1 contract

Samples: Securities Purchase Agreement (Replimune Group, Inc.)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!